United States’s biotechnological company Moderna on Monday announced that the first phase of the clinical trials of its experimental coronavirus vaccine has showed positive results.
As per reports, the company had launched a human clinical trial for the potential coronavirus vaccine in March this year.
According to a statement released by Moderna, protective antibodies were found in small groups of healthy volunteers aged between 18 to 55 years within a span of six weeks.
The company claimed that all the participants were found to have developed on day 15 after a single dose of the vaccine candidate mRNA-1273.
The first group which received two shots of the 25 microgram dose level of mRNA-1273 were found to have developed levels of binding antibodies similar to those seen in blood samples from people who have recovered from Covid-19 after a period of two weeks, the statement said.
On Day 43, the second group that received two shots of dose level 100 micrograms had binding antibodies significantly higher than what was observed in recovered Covid-19 patients.
Results from the third group, which received one shot of 250 microgram are not yet available.
“Based on the interim Phase 1 data, the Moderna-led Phase 2 study will be amended to study two dose levels, 50 µg and 100 µg, with the aim of selecting a dose for pivotal studies,” the company stated.
“Moderna anticipates the dose for the Phase 3 study to be between 25 µg and 100 µg and expects Phase 3 trial initiation in July, subject to finalization of the clinical trial protocol,” it added.